Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alimera To Resubmit Iluvien With No New Studies

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA has twice rebuffed Alimera’s marketing application for the intravitreal insert, which releases a corticosteroid to treat chronic diabetic macular edema, citing a bad risk/benefit balance. But after meeting with the agency in the second quarter, the company is confident a reanalysis of pivotal data will satisfy the agency.

Advertisement

Related Content

Alimera’s Diabetic Macular Edema Drug Iluvien Gets Third FDA Rejection
Alimera’s Iluvien Suffers Same Demise As Lucentis; NICE Rejects For DME
Financings Of The Fortnight: Bluebird Spots Brighter Skies For Gene Therapy Investment
Retinal Disease: Much Progress, Some Pain
FDA Issues "Complete Response" On Alimera's Iluvien; Eyes More Data
Alimera Raises $72 Million In IPO; Clips Share Price To $11 From Initial $15-$17 Range
Alimera Sciences Inc.

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel